A Multicentre Phase II Study of AZD1775 Plus Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Phase of Trial: Phase II
Latest Information Update: 25 Mar 2018
At a glance
- Drugs AZD-1775 (Primary) ; Carboplatin; Gemcitabine; Paclitaxel
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 14 Feb 2018 Planned primary completion date changed from 30 Aug 2018 to 23 May 2018.
- 10 Jan 2018 Planned End Date changed from 31 May 2018 to 29 Oct 2018.
- 10 Jan 2018 Planned primary completion date changed from 2 Mar 2018 to 30 Aug 2018.